As artificial intelligence becomes embedded in clinical trial infrastructure, researchers are raising a critical concern: opaque AI models risk amplifying health disparities rather than reducing them. A new analysis in npj Digital Medicine proposes a framework the authors call embedded transparency as a necessary condition for equitable AI-enabled trials.
AI systems are increasingly used to identify, stratify, and analyze participants in clinical trials. When these systems are black boxes, their biases can silently propagate across the trial lifecycle from eligibility screening through outcome measurement, potentially excluding underrepresented populations or encoding biased treatment assignments.
The embedded transparency framework has four pillars. First, ex ante interpretability ensures that how an AI model works is understood before deployment. Second, demographic auditability allows regulators and sponsors to detect when an algorithm performs differently across population subgroups. Third, documented uncertainty handling requires models to communicate when they are uncertain rather than produce falsely confident outputs. Fourth, stakeholder-relative explanation means different audiences from trial investigators to participants receive explanations matched to their needs.
The authors argue that post hoc explanations are insufficient for clinical trials where decisions affect patient access to experimental therapies. Transparency must be structurally integrated from the design phase, not bolted on after the fact.
The governance recommendations call for regulatory bodies to require embedded transparency as part of AI-enabled trial submissions, building on emerging frameworks from the FDA and EMA for algorithmic accountability in clinical research.
